AUM is a clinical-stage biopharmaceutical company aiming to democratize R&D with a focus on discovering, acquiring, and developing novel therapeutics in oncology. The company holds exclusive worldwide rights in all disease indications for 2 first-in-class technologies with strong composition of matter patents in all major territories. 1) MNK Inhibition and 2) Multi-Kinase Inhibition (PIM/PI3K/mTOR).
AUM utilizes a proprietary partnered AI-augmented platform to systematically discover and develop targeted cancer therapies focused on genetic targets. AUM’s most advanced program is Phase II ready in colorectal cancer, and 2 additional pre-clinical programs have clear pathways to orphan drug designation.
For 2 years in a row, the company has been awarded the Frost & Sullivan Asia-Pacific Biotech Entrepreneurial Company of the Year Award.
AUM utilizes a proprietary partnered AI-augmented platform to systematically discover and develop targeted cancer therapies focused on genetic targets. AUM’s most advanced program is Phase II ready in colorectal cancer, and 2 additional pre-clinical programs have clear pathways to orphan drug designation.
For 2 years in a row, the company has been awarded the Frost & Sullivan Asia-Pacific Biotech Entrepreneurial Company of the Year Award.
Location: Singapore
Employees: 11-50
Total raised: $27M
Founded date: 2018
Investors 1
| Date | Name | Website |
| - | SPRIM Glob... | sprim.net |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 13.10.2021 | Series A | $27M | - |
Mentions in press and media 8
| Date | Title | Description |
| 14.07.2023 | Hope For The Challenging Biotech Landscape in Singapore: Q&A With AUM Bioscience’s Vishal Doshi | The biomedical sciences field in Singapore has recently encountered a number of obstacles, with barriers hindering new startups from incorporating and existing companies facing liquidity issues. The closure of Tessa Therapeutics after faili... |
| 20.10.2022 | AUM Biosciences, a Global Biotechnology Company Developing Precision Oncology Therapeutics, Announces Plans to Become a Public Company via Merger with Mountain Crest Acquisition Corp. V | SINGAPORE and NEW YORK, Oct. 20, 2022 (GLOBE NEWSWIRE) — AUM Biosciences Pte. Ltd. (“AUM”), a clinical-stage biotechnology company, advancing a clinical stage pipeline designed to deploy multi-faceted inhibition strategies to reverse cancer... |
| 13.10.2021 | AUM Biosciences Raises USD$27M in Series A Funding | Vishal Doshi, CEO and Co-founder of AUM Biosciences AUM Biosciences, a Singapore-based biotech company, raised USD$27M in Series A funding. The round was led by Everlife with participation from SPRIM Global Investment. The company intends t... |
| 13.10.2021 | To advance targeted cancer therapies, AUM Biosciences secures US $27 M Series A funding | AUM Biosciences, a Singapore-based global clinical-stage biotech firm, has closed a US $27 million Series A funding round. Singapore-based Everlife (market access and distribution platform for analytical, medical, and lab products) and heal... |
| 13.10.2021 | AUM Biosciences announces closing of USD $27Million in a "Series A" Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapies | SINGAPORE, Oct. 13, 2021 /PRNewswire/ -- AUM Biosciences (AUM) today announced the successful completion of USD $27 million series A funding round. This will fuel AUM's vision of developing a world class biotech pipeline focused on drugging... |
| 12.10.2021 | AUM Biosciences announces closing of $27 million in a “Series A” Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapies | SINGAPORE and NEW YORK, October 12, 2021 – AUM Biosciences (AUM) today announced the successful completion of $27 million series A funding round. This will fuel AUM’s vision of developing a world class biotech pipeline focused on drugging w... |
| 12.10.2021 | AUM Biosciences announces closing of $27 million in a "Series A" Round of funding to advance its clinical stage pipeline of precision and targeted cancer therapies | NEW YORK and SINGAPORE, Oct. 12, 2021 /PRNewswire/ -- AUM Biosciences (AUM) today announced the successful completion of $27 million series A funding round. This will fuel AUM's vision of developing a world class biotech pipeline focused on... |
| 12.10.2021 | Biotech startup AUM Biosciences raises $27 mn from Everlife and SGI | Biotech startup AUM Biosciences announced on Tuesday it has raised $27 million (around Rs 200 crore) in a Series A funding round from Singapore-based private equity fund Everlife and SPRIM Global Investments (SGI), a health science-focused ... |